Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05706779 | Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | PHASE2 | RECRUITING | 30 | — | — | Feb 13, 2023 | May 31, 2029 | Sep 2, 2025 | 1 | France |
with centralised review after neoadjuvant treatment with encorafenib and cetuximab, in patients with RAS wild type localised colon or upper rectum cancer (CC) and carriers of the BRAF V600E mutation.
| Arm | Type | Description |
|---|---|---|
| Encorafenib + Cetuximab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Encorafenib Oral Capsule + Cetuximab | DRUG | Encorafenib: 4 capsules 75 mg/day (300 mg) , 7 days/7 during 6 weeks Cetuximab: 500mg/m2 intravenous route every 2 weeks (D1, D14, D28), for 3 cycles over 4 weeks. |
Inclusion Criteria: * Informed consent signed and dated by the patient and the investigator * Age ≥18 years at time of informed consent * Adenocarcinoma of the colon or of the upper rectum (supra-peritoneal) considered operable and histologically confirmed, localised, mutated BRAF V600E determined ...